Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals.

Ozaki S, Kushida I, Yamashita T, Hasebe T, Shirai O, Kano K.

J Pharm Sci. 2012 Nov;101(11):4220-30. doi: 10.1002/jps.23306. Epub 2012 Aug 28.

PMID:
22930424
2.

Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms.

Ozaki S, Minamisono T, Yamashita T, Kato T, Kushida I.

J Pharm Sci. 2012 Jan;101(1):214-22. doi: 10.1002/jps.22760. Epub 2011 Sep 14.

PMID:
21918988
3.

Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs.

Ozaki S, Kushida I, Yamashita T, Hasebe T, Shirai O, Kano K.

J Pharm Sci. 2013 Jul;102(7):2273-81. doi: 10.1002/jps.23588. Epub 2013 May 8.

PMID:
23658029
4.
5.

Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation.

Sun DD, Lee PI.

Mol Pharm. 2013 Nov 4;10(11):4330-46. doi: 10.1021/mp400439q. Epub 2013 Oct 14.

PMID:
24066837
6.

Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.

Sun DD, Lee PI.

Mol Pharm. 2015 Apr 6;12(4):1203-15. doi: 10.1021/mp500711c. Epub 2015 Mar 23.

PMID:
25775257
7.

In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.

Higashino H, Hasegawa T, Yamamoto M, Matsui R, Masaoka Y, Kataoka M, Sakuma S, Yamashita S.

Mol Pharm. 2014 Mar 3;11(3):746-54. doi: 10.1021/mp400465p. Epub 2014 Feb 6.

PMID:
24460473
8.

Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating Formulations.

Sun DD, Lee PI.

AAPS J. 2015 Nov;17(6):1317-26. doi: 10.1208/s12248-015-9825-6. Epub 2015 Sep 3.

PMID:
26338234
9.

Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.

Alhalaweh A, Bergström CA, Taylor LS.

J Control Release. 2016 May 10;229:172-82. doi: 10.1016/j.jconrel.2016.03.028. Epub 2016 Mar 19.

PMID:
27006280
10.

Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.

Berlin M, Przyklenk KH, Richtberg A, Baumann W, Dressman JB.

Eur J Pharm Biopharm. 2014 Nov;88(3):795-806. doi: 10.1016/j.ejpb.2014.08.011. Epub 2014 Sep 6.

PMID:
25195981
11.
12.

Quantitative analysis of the effect of supersaturation on in vivo drug absorption.

Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S.

Mol Pharm. 2010 Oct 4;7(5):1431-40. doi: 10.1021/mp100109a. Epub 2010 Aug 12.

PMID:
20704264
13.

Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.

Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, Porter CJ.

Mol Pharm. 2013 May 6;10(5):1874-89. doi: 10.1021/mp3006566. Epub 2013 Mar 27.

PMID:
23480483
14.
15.

Assessment of the amorphous "solubility" of a group of diverse drugs using new experimental and theoretical approaches.

Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS.

Mol Pharm. 2015 Feb 2;12(2):484-95. doi: 10.1021/mp500571m. Epub 2014 Dec 29.

PMID:
25495614
16.

Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.

Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ.

Pharm Res. 2013 Dec;30(12):2976-92. doi: 10.1007/s11095-013-1126-0. Epub 2013 Jul 4. Review.

PMID:
23824582
17.

Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles.

Cheow WS, Kiew TY, Yang Y, Hadinoto K.

Mol Pharm. 2014 May 5;11(5):1611-20. doi: 10.1021/mp400788p. Epub 2014 Apr 4.

PMID:
24669821
18.

Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an in vitro model simulating the stomach and duodenum.

Mitra A, Fadda HM.

Mol Pharm. 2014 Aug 4;11(8):2835-44. doi: 10.1021/mp500196f. Epub 2014 Jul 15.

PMID:
25025699
19.

Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.

DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO 3rd.

Mol Pharm. 2008 Nov-Dec;5(6):968-80. doi: 10.1021/mp800042d.

PMID:
19434851
20.

Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?

Murdande SB, Pikal MJ, Shanker RM, Bogner RH.

J Pharm Sci. 2011 Oct;100(10):4349-56. doi: 10.1002/jps.22643. Epub 2011 May 31.

PMID:
21630280
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk